Send to

Choose Destination
FEBS Open Bio. 2017 Mar 21;7(5):627-635. doi: 10.1002/2211-5463.12122. eCollection 2017 May.

Screening and identification of the tumor-associated antigen CK10, a novel potential liver cancer marker.

Zhu Z1,2, Liu Z1, Liu Y1, Wang C1, Li R1, Liu H1, Gu B1, Li G3, Zhang S1,4.

Author information

School of Life Sciences Zhengzhou University China.
Xinyang Vocational and Technical College Xinyang China.
Henan Key Laboratory of Bioactive Molecules Zhengzhou University China.
Collaborative Innovation Center of New Drug Research and Safety Evaluation Zhengzhou China.


Hepatocellular carcinoma (HCC) is a malignancy that is associated with high mortality rates in Asia. These tumors are highly invasive and their etiology is frequently unknown. Thus, most patients are diagnosed in the middle and late stages of the disease, and thus do not have sufficient time for therapy. Therefore, it is essential to study the early diagnosis and treatment of HCC; in this regard, the study of tumor-associated antigens has received much attention. Here, antigens from the human primary HCC cell line, QGY-7703, were used to immunize mice in order to prepare monoclonal antibodies. The specific antigen recognized by antibody 11C3 was purified from total protein lysates of QGY-7703 by immunoaffinity chromatography. The validity of the candidate antigen as a new HCC-associated marker was tested using SDS/PAGE, western blot, HPLC-ESI-MS/MS, and RT-qPCR. Our results showed that the levels of CK10 in HCC-derived cell lines were significantly higher than those in normal liver cells. Thus, we suggest that CK10 may be involved in the formation and development of HCC, and may be a therapeutically targetable tumor-associated antigen.


antibody; biomarker; hepatocellular carcinoma; tumor‐associated antigen

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center